Back to Directory
Last Updated: 06/05/2026
Alchemab Therapeutics
London
Founded 2019
Antibody discovery platform identifying therapeutics from resilient individuals
Alchemab Therapeutics is a clinical-stage biopharmaceutical company developing antibody therapeutics for neurodegenerative diseases, oncology, and immunology.
Its platform combines deep B cell sequencing and machine learning to identify naturally protective antibodies from individuals resilient to specific diseases.
The company's lead programme for amyotrophic lateral sclerosis entered Phase 1 trials following a licensing agreement with Eli Lilly.
Alchemab operates from London with research laboratories in Cambridge.
Company Notes
Member of